An honest comparison to help you choose the right weight loss medication for your goals.
Average Weight Loss
Brand names: Mounjaro, Zepbound
Average Weight Loss
Brand names: Ozempic, Wegovy
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 | GLP-1 Only |
| Average Weight Loss | significant | moderate |
| Maximum in Trials | 26.6% | 17.4% |
| Dosing Frequency | Once Weekly | Once Weekly |
| FDA Approval (Weight Loss) | 2023 | 2021 |
| Blood Sugar Control | Excellent | Very Good |
| Muscle Preservation | Better | Good |
| Time to See Results | 1-2 weeks | 2-4 weeks |
The dual-agonist mechanism delivers approximately 40% more weight loss compared to single-action GLP-1 medications.
GIP receptor activation enhances fat burning and muscle preservation - benefits that GLP-1 alone cannot provide.
Represents the newest generation of weight loss medication, incorporating lessons from GLP-1-only drugs.
In landmark clinical research, Tirzepatide has shown exceptional results, with some patients losing over a quarter of their body weight.
15,000+ trial participants
Extensive safety and efficacy data
Multiple FDA approvals
For diabetes (Mounjaro) and weight loss (Zepbound)
Published in top journals
New England Journal of Medicine, JAMA
*Data from published clinical research on GLP-1 and dual-agonist therapies
Not sure which is right for you? Our team can help.
Free ConsultationChoose the most effective weight loss treatment available. Start your Tirzepatide journey today.